A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25602-25618

  Morandi, Fabio ^a   Morandi, Barbara ^b   Horenstein, Alberto L ^c   Chillemi, Antonella ^c   Quarona, Valeria ^c   Zaccarello, Gianluca ^c   Carrega, Paolo ^a   Ferlazzo, Guido ^d,e   Mingari, Maria Cristina ^b   Moretta, Lorenzo ^a   Pistoia, Vito ^a   Malavasi, Fabio ^c  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

Adenosine; Ectoenzymes; Immunosuppression; Melanoma

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE PHOSPHATE; CD203A ANTIGEN; CD38 ANTIGEN; CD39 ANTIGEN; CD8 ANTIGEN; LYMPHOCYTE ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE; S6 KINASE; STAT1 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CD38 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN; NT5E PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY T LYMPHOCYTE; MOLECULAR MECHANICS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; CELL PROLIFERATION; COCULTURE; ENZYMOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KINETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ADENOSINE; ANTIGENS, CD38; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; KINETICS; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84944463019     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4693     Document Type: Article

References (48)

1. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013; 19:355-367.
2. Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, Serra S, Malavasi F. A CD38/CD203a/ CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology. 2013; 2:26.
3. Fedele G, Sanseverino I, D'Agostino K, Schiavoni I, Locht C, Horenstein AL, Malavasi F, Ausiello CM. Unconventional adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine. Journal of Leukocyte Biology. 2015.
4. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013; 13:842-857.
5. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol. 2008; 32:527-535.
6. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010; 70:2245-2255.
7. Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009; 183:5487-5493.
8. Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, Jackson EK, Gorelik E. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosineprotein kinase A type I signaling. Cancer Res. 2007; 67:5949-5956.
9. Ghiringhelli F, Bruchard M, Chalmin F, Rebe C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol. 2012; 473712:14.
10. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011; 121:2371-2382.
11. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013; 110:11091-11096.
12. Sadej R, Spychala J, Skladanowski AC. Expression of ecto- 5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 2006; 16:213-222.
13. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer. 2012; 106:1446-1452.
14. Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol Oncol Res. 2013; 19:811-814.
15. Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxiainducible factor-1alpha in gastric carcinoma. World J Gastroenterol. 2013; 19:1912-1918.
16. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997; 57:2602-2605.
17. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, Arra C, Cicala C, Pinto A, Morello S. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol. 2012; 189:2226-2233.
18. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011; 71:2892-2900.
19. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010; 107:1547-1552.
20. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, Smyth MJ. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012; 72:2190-2196.
21. Zhou X, Zhi X, Zhou P, Chen S, Zhao F, Shao Z, Ou Z, Yin L. Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep. 2007; 17:1341-1346.
22. Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE, Murakami T, Robson SC. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology. 2010; 139:1030-1040.
23. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011; 334:1573-1577.
24. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A. 2013; 110:14711-14716.
25. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia. 2013; 15:1400-1409.
26. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103:13132-13137.
27. Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S, Rodenko B, Zwart W, Evers B, Horlings H, Ajouaou A, Zevenhoven J, et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A. 2013; 110:5139-5144.
28. Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, Pende D, Misefari A, Moretta A, Mingari MC, Moretta L, Ferlazzo G. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLArelated effector mechanisms and role of unlicensed NK cells. PLoS One. 2009; 4:e8132.
29. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012; 72:1407-1415.
30. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114:1537-1544.
31. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014; 74:665-674.
32. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5:3006504.
33. Blay J. Adenosine and Tumor Microenvironment. In: Schwab M, ed. Encyclopedia of Cancer: SpringerBerlin Heidelberg), 2012; PP. 49-52
34. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012; 33:231-237.
35. Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, Roato I, Morandi F, Marimpietri D, Faccani G, Martella E, Pistoia V, Giuliani N, Horenstein AL, Malavasi F. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci. 2015; 1335:10-22.
36. Zhang H, Conrad DM, Butler JJ, Zhao C, Blay J, Hoskin DW. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3', 5'-monophosphate and phosphatases. J Immunol. 2004; 173:932-944.
37. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997; 90:1600-1610.
38. Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal. 2011; 11:320-339.
39. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2012; 441:1-21.
40. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994; 265:808-811.
41. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol. 1999; 162:4472-4481.
42. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol. 2012; 13:907-915.
43. Ma XM, Blenis J. Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol. 2009; 10:307-318.
44. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev. 2001; 21:105-128.
45. Kellenberger E, Kuhn I, Schuber F, Muller-Steffner H. Flavonoids as inhibitors of human CD38. Bioorg Med Chem Lett. 2011; 21:3939-3942.
46. Thorn JA, Jarvis SM. Adenosine transporters. Gen Pharmacol. 1996; 27:613-620.
47. Chu S, Xiong W, Parkinson FE. Effect of ecto- 5'-nucleotidase (eN) in astrocytes on adenosine and inosine formation. Purinergic Signal. 2014; 10:603-609.
48. Joseph SM, Pifer MA, Przybylski RJ, Dubyak GR. Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation. Br J Pharmacol. 2004; 142:1002-1014.